Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2021

01-08-2021 | Opioids | Research Article

Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample

Authors: Kirk E. Evoy, Jordan R. Covvey, Alyssa M. Peckham, Kelly R. Reveles

Published in: International Journal of Clinical Pharmacy | Issue 4/2021

Login to get access

Abstract

Background Reports of gabapentinoid (gabapentin and pregabalin) misuse are on the rise, but few studies have assessed this within the general US population. Objective Describe lifetime misuse/abuse/non-prescribed obtainment of gabapentinoids and descriptive characteristics associated with such actions in a US general population sample. Setting This cross-sectional questionnaire was administered online by Qualtrics® research panel aggregator via quota-based sampling. Methods Data were collected from a sample of respondents that mirrored the general US population aged 18–59 years with regards to age, geographic region, ethnicity, income, and education level, based on most recent census data. Misuse/abuse/non-prescribed obtainment was collectively defined as use of a gabapentinoid for reasons other than a diagnosed medical condition, using with the intention of altering one’s state of consciousness, or obtaining without a prescription. A multivariable logistic regression model was created to predict misuse/abuse/non-prescribed obtainment of gabapentinoids, incorporating relevant covariates. Main outcome measure Proportion of sample indicating lifetime misuse/abuse/non-prescribed obtainment of gabapentinoids. Results Among 1,843 respondents, 121 (6.6%) reported gabapentinoid misuse/abuse/non-prescribed obtainment. Specifically, 2.1% (n = 39) and 1.5% (n = 27) of respondents for gabapentin and pregabalin, respectively, met study criteria for abuse. Opioids were the most common medication co-administered with gabapentinoids (among 50–70% of respondents) for misuse/abuse. Previous treatment for addiction (OR: 2.61, 95% CI: 1.32–5.14, p = 0.005) and the total attitudinal risk score (OR: 1.14, 95% CI: 1.09–1.19, p < 0.001) were associated with gabapentinoid misuse/abuse/non-prescribed obtainment. Conclusion Among those surveyed, 6.6% reported previous gabapentinoid misuse/abuse/non-prescribed obtainment, providing one of the first estimates within a nationally distributed, US general population sample.
Literature
3.
go back to reference Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. J Managed Care Pharm. 2002;8(4):266–71.CrossRef Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. J Managed Care Pharm. 2002;8(4):266–71.CrossRef
4.
go back to reference Evoy KE, Morrison M, Saklad SR. Pregabalin and gabapentin abuse: a systematic review. Drugs. 2017;77(4):403–26.CrossRef Evoy KE, Morrison M, Saklad SR. Pregabalin and gabapentin abuse: a systematic review. Drugs. 2017;77(4):403–26.CrossRef
5.
go back to reference Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.CrossRef Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.CrossRef
6.
go back to reference Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017 Aug;37(8):763–73.CrossRef Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017 Aug;37(8):763–73.CrossRef
7.
go back to reference Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA. Predictors of gabapentin overuse with or without concomitant opioids in a commercially-insured US population. Pharmacotherapy. 2018;38(4):436–43.CrossRef Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA. Predictors of gabapentin overuse with or without concomitant opioids in a commercially-insured US population. Pharmacotherapy. 2018;38(4):436–43.CrossRef
9.
go back to reference Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(9):1083–6.CrossRef Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(9):1083–6.CrossRef
10.
go back to reference Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018;186:80–5.CrossRef Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018;186:80–5.CrossRef
11.
go back to reference Kapil V, Green JL, Le Lait MC, et al. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–1.CrossRef Kapil V, Green JL, Le Lait MC, et al. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–1.CrossRef
12.
go back to reference Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018 Aug;17(11):109–16.CrossRef Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018 Aug;17(11):109–16.CrossRef
13.
go back to reference Patterson JA, Holdford DA. Pharmacy patronage and service utilization: associations with patient sociodemographic and health characteristics. J Am Pharm Assoc. 2019;59(5):660-9.e2.CrossRef Patterson JA, Holdford DA. Pharmacy patronage and service utilization: associations with patient sociodemographic and health characteristics. J Am Pharm Assoc. 2019;59(5):660-9.e2.CrossRef
14.
go back to reference Varisco TJ, Fleming ML, Bapat SS, Wanat MA, Thornton D. Health care practitioner counseling encourages disposal of unused opioid medications. J Am Pharm Assoc. 2019;59(6):809-15.e5.CrossRef Varisco TJ, Fleming ML, Bapat SS, Wanat MA, Thornton D. Health care practitioner counseling encourages disposal of unused opioid medications. J Am Pharm Assoc. 2019;59(6):809-15.e5.CrossRef
15.
go back to reference Soucy JN, Hadjistavropoulos HD. Treatment acceptability and preferences for managing severe health anxiety: perceptions of internet-delivered cognitive behavior therapy among primary care patients. J Behav Ther Exp Psychiat. 2017;57:14–24.CrossRef Soucy JN, Hadjistavropoulos HD. Treatment acceptability and preferences for managing severe health anxiety: perceptions of internet-delivered cognitive behavior therapy among primary care patients. J Behav Ther Exp Psychiat. 2017;57:14–24.CrossRef
16.
go back to reference Bhutada NS, Rollins BL. Disease-specific direct-to-consumer advertising of pharmaceuticals: an examination of endorser type and gender effects on consumers’ attitudes and behaviors. Res Social Adm Pharm. 2015;11:891–900.CrossRef Bhutada NS, Rollins BL. Disease-specific direct-to-consumer advertising of pharmaceuticals: an examination of endorser type and gender effects on consumers’ attitudes and behaviors. Res Social Adm Pharm. 2015;11:891–900.CrossRef
17.
go back to reference Prather AA, Gottlieb LM, Giuse NB, et al. National academy of medicine social and behavioral measures: associations with self-reported health. Am J Prev Med. 2017;53(4):449–56.CrossRef Prather AA, Gottlieb LM, Giuse NB, et al. National academy of medicine social and behavioral measures: associations with self-reported health. Am J Prev Med. 2017;53(4):449–56.CrossRef
18.
go back to reference Huang MY, Huston SA, Perri M. Consumer preferences for the predictive genetic test for alzheimer disease. J Genet Counsel. 2014;23:172–8.CrossRef Huang MY, Huston SA, Perri M. Consumer preferences for the predictive genetic test for alzheimer disease. J Genet Counsel. 2014;23:172–8.CrossRef
19.
go back to reference Palmer-Wackerly AL, Krieger JL, Rhodes ND. The role of health care provider and partner decisional support in patients’ cancer treatment decision-making satisfaction. J Health Commun. 2016;22(1):10–9.CrossRef Palmer-Wackerly AL, Krieger JL, Rhodes ND. The role of health care provider and partner decisional support in patients’ cancer treatment decision-making satisfaction. J Health Commun. 2016;22(1):10–9.CrossRef
20.
go back to reference Guillory J, Kim A, Murphy J, et al. Comparing twitter and online panels for survey recruitment of e-cigarette users and smokers. J Med Internet Res. 2016;18(11):e288.CrossRef Guillory J, Kim A, Murphy J, et al. Comparing twitter and online panels for survey recruitment of e-cigarette users and smokers. J Med Internet Res. 2016;18(11):e288.CrossRef
21.
go back to reference Schommer JC, Tieger PD, Olson AW, et al. Development of the Adherence Predictive Index (API) for medication taking. Innov Pharm. 2016;7(1):Article 11. Schommer JC, Tieger PD, Olson AW, et al. Development of the Adherence Predictive Index (API) for medication taking. Innov Pharm. 2016;7(1):Article 11.
22.
go back to reference Olson AW, Schommer JC, Mott DA, et al. Financial hardship from purchasing medications for senior citizens before and after the medicare modernization act of 2003 and the patient protection and affordable care act of 2010: findings from 1998, 2001, and 2015. J Manag Care Spec Pharm. 2016;22(10):1150–8.PubMed Olson AW, Schommer JC, Mott DA, et al. Financial hardship from purchasing medications for senior citizens before and after the medicare modernization act of 2003 and the patient protection and affordable care act of 2010: findings from 1998, 2001, and 2015. J Manag Care Spec Pharm. 2016;22(10):1150–8.PubMed
23.
go back to reference Lanz JJ, Bruk-Lee V. Resilience as a moderator of the indirect effects of conflict and workload on job outcomes among nurses. J Adv Nurs. 2017;73:2973–86.CrossRef Lanz JJ, Bruk-Lee V. Resilience as a moderator of the indirect effects of conflict and workload on job outcomes among nurses. J Adv Nurs. 2017;73:2973–86.CrossRef
24.
go back to reference Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European medicines agency’s “suspected adverse drug reactions” database. CNS Drugs. 2016;30(7):647–54.CrossRef Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European medicines agency’s “suspected adverse drug reactions” database. CNS Drugs. 2016;30(7):647–54.CrossRef
25.
go back to reference Häkkinen M, Vuori E, Kalso E, Gergov M, Ojanperä I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014 ;241:1–6.CrossRef Häkkinen M, Vuori E, Kalso E, Gergov M, Ojanperä I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014 ;241:1–6.CrossRef
26.
go back to reference Klein-Schwartz W, Shepherd JG, Gorman S, Dahl B. Characterization of gabapentin overdose using a poison center case series. J Toxicol Clin Toxicol. 2003;41(1):11–5.CrossRef Klein-Schwartz W, Shepherd JG, Gorman S, Dahl B. Characterization of gabapentin overdose using a poison center case series. J Toxicol Clin Toxicol. 2003;41(1):11–5.CrossRef
27.
go back to reference Asomaning K, Abramsky S, Liu Q, Zhou X, Sobel RE, Watt S. Pregabalin prescriptions in the United Kingdom: a drug utilization study of The Health Improvement Network (THIN) primary care database. Int J Clin Pract. 2016;70(5):380–8.CrossRef Asomaning K, Abramsky S, Liu Q, Zhou X, Sobel RE, Watt S. Pregabalin prescriptions in the United Kingdom: a drug utilization study of The Health Improvement Network (THIN) primary care database. Int J Clin Pract. 2016;70(5):380–8.CrossRef
28.
go back to reference Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85(6):1260–9.CrossRef Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85(6):1260–9.CrossRef
30.
go back to reference McNamara S, Stokes S, Kilduff R, Shine A. Pregabalin abuse amongst opioid substitution treatment patients. Ir Med J. 2015;108(10):309–10.PubMed McNamara S, Stokes S, Kilduff R, Shine A. Pregabalin abuse amongst opioid substitution treatment patients. Ir Med J. 2015;108(10):309–10.PubMed
31.
go back to reference Vickers Smith R, Boland EM, Young AM, et al. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychol Addict Behav. 2018;32(1):115–21.CrossRef Vickers Smith R, Boland EM, Young AM, et al. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychol Addict Behav. 2018;32(1):115–21.CrossRef
32.
go back to reference Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf. 2018;41(2):213–28.CrossRef Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf. 2018;41(2):213–28.CrossRef
33.
go back to reference Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.CrossRef Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.CrossRef
34.
go back to reference Gomes T, Greaves S, van den Brink W, Antoniou T, Mamdani MM. Pregabalin and the risk of opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732–4.CrossRef Gomes T, Greaves S, van den Brink W, Antoniou T, Mamdani MM. Pregabalin and the risk of opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732–4.CrossRef
Metadata
Title
Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample
Authors
Kirk E. Evoy
Jordan R. Covvey
Alyssa M. Peckham
Kelly R. Reveles
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01217-8

Other articles of this Issue 4/2021

International Journal of Clinical Pharmacy 4/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.